Latest Commercialisation News

Neurizon Therapeutics has secured a critical five-year supply agreement with Elanco Animal Health for GMP-grade monepantel, underpinning the commercialisation readiness of its lead ALS drug candidate NUZ-001.

Victory Metals has achieved a major processing milestone at its North Stanmore Project, producing a 7.1% Total Rare Earth Oxide concentrate with 40% heavy rare earth oxides through continuous flotation at pilot scale.

Island Pharmaceuticals has won a key regulatory boost as the US FDA granted Orphan Drug Designation to Galidesivir for post-exposure prophylaxis of Marburg virus disease, enhancing its commercial and development prospects.

Harvest Technology Group has transitioned from assessing to actively executing its international defence market strategy by engaging a US national security advisory firm and appointing Dr Oleksandra Molloy as Defence Strategic Advisor for Europe.

SciDev Ltd has completed a strategic review addressing past underperformance and is refocusing on an integrated water solutions platform targeting core markets. The company confirmed FY26 guidance with revenue of $82 to $87 million and underlying EBITDA of approximately $4 million, while maintaining a sound balance sheet.

Memphasys has locked in a 12-month exclusive supply agreement with Monash IVF for its Felix™ sperm selection system, marking its biggest commercial contract to date and setting a foundation for recurring revenue.

Strike Energy’s Walyering West-1 well delivered a stabilised gas flow of 11 MMscf/d from the C1 sand, confirming a clean, condensate-rich gas accumulation near existing infrastructure in the Perth Basin.

Nanoveu’s EMASS technology achieves real-time, always-on keyword spotting using bone-conduction vibration on the ECS-DoT edge AI chip at under 1 milliwatt power, eliminating the need for microphones and overcoming key challenges in wearable voice interfaces.

Critical Resources has achieved a key milestone by depositing a complete solid-state battery cathode layer in one dry, solvent-free step, potentially simplifying and cutting costs in battery production for high-demand sectors.

LTR Pharma has confirmed it disclosed a binding US commercialisation agreement for ROXUS promptly after signing, responding to ASX scrutiny over pre-announcement trading activity.

FBR Ltd is set to slash its share count by consolidating every 50 securities into one, impacting ordinary shares, performance rights, and options. The move awaits shareholder approval with critical milestones scheduled throughout July 2026.

PathKey.AI (ASX:PKY) confirmed no undisclosed price-sensitive information amid a recent jump in its share price and trading volume, attributing the move to prior announcements and investor interest in AI opportunities.